Related references
Note: Only part of the references are listed.A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells
Marco Ruella et al.
BLOOD (2020)
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Laerke J. B. Brandt et al.
FRONTIERS IN IMMUNOLOGY (2020)
Synthetic immunity by remote control
Lena Gamboa et al.
THERANOSTICS (2020)
Steering CAR T cells to distinguish friend from foe
Hillary G. Caruso et al.
ONCOIMMUNOLOGY (2019)
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
Shivani Srivastava et al.
CANCER CELL (2019)
A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy
Roy L. Kao et al.
HUMAN GENE THERAPY (2019)
Target selection for CAR-T therapy
Jianshu Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
Stefanie Koristka et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Shivani Srivastava et al.
JOURNAL OF IMMUNOLOGY (2018)
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Yanyu Pang et al.
MOLECULAR CANCER (2018)
A Rapamycin-Activated Caspase 9-Based Suicide Gene
Maria Stavrou et al.
MOLECULAR THERAPY (2018)
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zijun Zhao et al.
ACTA PHARMACEUTICA SINICA B (2018)
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Erhao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Dina Schneider et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal et al.
CELL (2016)
Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells
John Maher et al.
IMMUNITY (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Versatile strategy for controlling the specificity and activity of engineered T cells
Jennifer S. Y. Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects
Shengmeng Di et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Design of chimeric antigen receptors with integrated controllable transient functions
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
Notch signaling: An emerging therapeutic target for cancer treatment
Xun Yuan et al.
CANCER LETTERS (2015)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules
Min Soo Kim et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Markus Chmielewski et al.
IMMUNOLOGICAL REVIEWS (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Improving the safety of cell therapy products by suicide gene transfer
Benjamin S. Jones et al.
Frontiers in Pharmacology (2014)
The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
Tessa Gargett et al.
FRONTIERS IN PHARMACOLOGY (2014)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Cell-Based Therapeutics: The Next Pillar of Medicine
Michael A. Fischbach et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Kevin J. Curran et al.
JOURNAL OF GENE MEDICINE (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
The Tumor Lysis Syndrome
Scott C. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
Monica Casucci et al.
JOURNAL OF CANCER (2011)
Monoclonal antibody-induced cytokine-release syndrome
Peter J. Bugelski et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
Fabio Ciceri et al.
LANCET ONCOLOGY (2009)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies
M Introna et al.
HUMAN GENE THERAPY (2000)
Share Paper
